Thursday, February 22, 2024
HomeBusinessHuman Chorionic Gonadotropin (HCG) Market Share, Growth, Size, Trends and Forecast 2023-2028

Human Chorionic Gonadotropin (HCG) Market Share, Growth, Size, Trends and Forecast 2023-2028

Html code here! Replace this with any non empty raw html code and that's it.

IMARC Group, a leading market research company, has recently published a report titled “Human Chorionic Gonadotropin (HCG) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The study provides a detailed analysis of the industry, including Human Chorionic Gonadotropin (HCG) market size, share, trends and growth forecasts. The report also includes competitive and regional analysis and highlights the latest developments in the market.

How big is the human chorionic gonadotropin (HCG) market?

global human chorionic gonadotropin (HCG) market. size reached $903.78 million in 2022. Looking ahead, IMARC Group expects the market to reach $1,411.06 million by 2028, exhibiting a CAGR of 7.62% during 2023-2028 .

What is Human Chorionic Gonadotropin (HCG)?

Human chorionic gonadotropin (HCG) is a chemical produced by the syncytiotrophoblastic cells of the placenta during pregnancy. This chemical can be found in several parts of the body, including the blood, urine, liver, colon, and pituitary glands. Its main function is to stimulate the corpus luteum, which helps produce progesterone to maintain pregnancy. In clinical applications, HCG is extracted and purified from the urine of pregnant women using techniques such as ion-exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility issues, improve the chances of pregnancy, help with testosterone and sperm production, and treat cryptorchidism in male children. Consequently, human chorionic gonadotropin (HCG) finds widespread use in fertility clinics and research institutions across the globe.

Request a sample copy of this report:

What are the growth prospects and trends in the Human Chorionic Gonadotropin (HCG) Industry?

The human chorionic gonadotropin (HCG) market is primarily driven by the increasing prevalence of female infertility caused by uterine disorders, blocked fallopian tubes, polycystic ovary syndrome (PCOS), and endocrine system disorders. In addition, the increasing use of HCG in assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility is acting as another important factor driving growth. Moreover, the expanding employment of HCG in combination with other fertility drugs to increase the chances of pregnancy in women is further catalyzing the growth of the market. In addition, the increasing adoption of HCG to increase testosterone levels, stimulate fertility and promote sexual function in men suffering from obesity and type 2 diabetes, which often leads to disorders associated with hypogonadism, is also influencing positively in the global market. In addition, increasing production of HCG using recombinant technology to provide identical properties and improve safety compared to natural source HCG, leading to increased patient tolerance, is expected to drive the market in the coming years.

What is involved in market segmentation?

The report has segmented the market into the following categories:

Technology Insights:

  • Natural resource extraction
  • Recombinant Technology

Therapeutic field insights:

  • Treatment of female infertility
  • Male hypogonadism
  • Oligospermic treatment
  • Others

End User Insights:

  • Fertility Clinics
  • Research institutions
  • Others

Market breakdown by region:

  • North America (United States, Canada)
  • Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, others)
  • Latin America (Brazil, Mexico, others)
  • Middle East and Africa

Who are the major players operating in the industry?

The report covers key market players including:

  • Biocare Medical LLC,
  • Ferring Pharmaceuticals,
  • Fresenius SE & Co. KGaA,
  • Kamiya Biomedical Company (Nitto Boseki Co. Ltd.),
  • Lee Biosolutions Inc. (Oy Medix Biochemica Ab),
  • Merck & Co Inc.,
  • Prospec-Tany Technogene Ltd.,
  • Scripps Laboratories Inc.,
  • Sun Pharmaceutical Industries Limited

Ask the analyst for the sample report:

If you need specific information that is not currently within the scope of the report, we will provide it to you as part of the customization.

around us

IMARC Group is a leading market research company providing management strategy and market research worldwide. We partner with clients across sectors and regions to identify their highest value opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include key market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and new processing methods are at the forefront of the company’s expertise.

Contact us

The IMARC group
Email: [email protected]
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal



Please enter your comment!
Please enter your name here


Most Popular

Recent Comments